Comparing Trident Brands (OTCMKTS:TDNT) and Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS) and Trident Brands (OTCMKTS:TDNT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Volatility & Risk

Evolus has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Trident Brands has a beta of -4.1, indicating that its share price is 510% less volatile than the S&P 500.

Insider & Institutional Ownership

90.7% of Evolus shares are held by institutional investors. 5.9% of Evolus shares are held by company insiders. Comparatively, 33.9% of Trident Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Evolus and Trident Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-20.49%	-759.04%	-23.47%
Trident Brands	N/A	N/A	N/A

Analyst Ratings

This is a summary of current recommendations for Evolus and Trident Brands, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	3	0	2.40
Trident Brands	0	0	0	0	0.00

Evolus presently has a consensus target price of $21.25, suggesting a potential upside of 197.37%. Given Evolus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Evolus is more favorable than Trident Brands.

Earnings and Valuation

This table compares Evolus and Trident Brands”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$285.82 million	1.62	-$50.42 million	($0.92)	-7.77
Trident Brands	N/A	N/A	N/A	N/A	N/A

Trident Brands has lower revenue, but higher earnings than Evolus.

Summary

Evolus beats Trident Brands on 6 of the 10 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Trident Brands

Trident Brands Incorporated, together with its subsidiaries, focuses on developing branded consumer products and ingredients in the nutritional supplement, life sciences, and food and beverage categories in the United States and Canada. The company develops, markets, and sells a portfolio of DHA supplements under the Brain Armor brand. It also holds various banking facilities; and licenses associated with the manufacturing, importation, and sale of natural health and nutrition products. The company was formerly known as Sandfield Ventures Corp. and changed its name to Trident Brands Incorporated in July 2013. Trident Brands Incorporated was incorporated in 2007 and is based in Boca Raton, Florida.